Results 71 to 80 of about 1,341 (168)

Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review

Clinical Ophthalmology, 2022
Mizuki Tagami,1 Shigeru Honda,1 Atsushi Azumi2 1Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan; 2Ophthalmology Department and Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo ...
Tagami M, Honda S, Azumi A
doaj  

Teprotumumab divergently alters fibrocyte gene expression: Implications for thyroid-associated ophthalmopathy

, 2022
Research report supplemental figure.Context: Teprotumumab, an IGF-I receptor inhibitor (IGF-IR), is effective in thyroid-associated ophthalmopathy (TAO).
Smith, Terry
core   +1 more source

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study

, 2022
Purpose: To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonresponsive or who experienced a disease flare. Design: The Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in an ...
Eckstein A., Wester S., Salvi M., Francis-Sedlak M., Harris G. J., Marino M., Holt R. J., Smith T. J., Ponto K. A., Fuhrer-Sakel D., Antonelli A., Schiffman J., Fowler B. T., Dailey R., Douglas R. S., Kahaly G. J., Tang R., Ugradar S., Jain A. P., Marcocci C., Sile S., Elflein H.   +21 more
core   +1 more source

Intraocular and extraocular manifestations of thyroid dysfunction in Danish patients – A Nationwide Study

Acta Ophthalmologica, Volume 102, Issue S283, Page 3-25, September 2024.
Lena Boulakh
wiley   +1 more source

Real World Experience with Teprotumumab in Patients with Dysthyroid Optic Neuropathy (DON)

, 2023
Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life (QOL) in patients with active thyroid eye disease (TED) in clinical trials.1,2 The trials excluded ...
Madhura Tamhankar; Alvin Relucio
core  

Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab

, 2023
Introduction: Pretibial myxedema (PTM) is a localized thyroid-associated dermopathy characterized by local thickening of the skin of the lower extremities. It mostly develops after the onset of thyroid eye disease (TED).
Niedzialkowska, Ewelina M, Banka, Ajaz, Pokharel, Ashbita   +2 more
core   +1 more source

Post-marketing Surveillance of Hearing-related Adverse Events in Patients With TED Treated With Teprotumumab

, 2022
Teprotumumab (TEPEZZA), an insulin-like growth factor-1 receptor inhibitor was shown to improve proptosis, diplopia, and inflammation in thyroid eye disease (TED).
Kimberly Cockerham; Shayna Melvani; Pamela Rakestraw
core  

The Role of Teprotumumab in the Treatment of Diplopia Due to Thyroid Eye Disease

, 2023
Thyroid Eye Disease (TED) is a vision threatening condition caused by inflammatory damage to the periocular tissue. Teprotumumab is an IGF-1R antibody that was FDA approved for the management of TED in 2020, although much is yet to be elucidated ...
Shwetha Mudalegundi; Peng Huang; Amanda Henderson; Andrew Carey
core  

Teprotumumab Treatment in a Patient With Longstanding Thyroid Eye Disease

, 2021
Thyroid eye disease (TED), is an autoimmune disorder of retrobulbar tissue.1 The most common presentations of TED include eyelid retraction, dryness, injection, diplopia, blindness or proptosis.1 During the active phase, treatments include systemic ...
Rachel Davis; James Williams; Erik Happ
core  

The association of race with thyroid eye disease presentation and outcomes

Frontiers in Ophthalmology
IntroductionClassification of thyroid eye disease (TED) is largely based on guidelines developed in Europe and North America. Few studies have investigated the presentation and treatment of TED in Black populations.
Diane Wang, Diane Wang, Diane Wang, Charlotte Marous, Charlotte Marous, Charlotte Marous, Pelin Celiker, Wenyu Deng, Wenyu Deng, Eva Kristoferson, Ali Elsayed, Roman Shinder, Roman Shinder, Roman Shinder, Nickisa Hodgson, Nickisa Hodgson   +15 more
doaj   +1 more source